Columbia University Medical Center to Validate Rosetta Genomics’ CUP Diagnostic
Rosetta Genomics this week announced that it has signed a deal under which Columbia University Medical Center will conduct clinical validation work for the company’s cancer of unknown primary diagnostic.
Under the arrangement, Rosetta said it will provide CUMC with its protocol for diagnosing the primary origin of metastatic cancers, which will then be tested and validated using unknown samples provided by the medical center.
"Establishing a relationship with an experienced research team at a state-of-the-art [clinical laboratory improvement amendments]-approved laboratory is essential to the rapid advancement of our CUP diagnostic," Dalia Cohen, global head of research and development at Rosetta, said in a statement.
The deal with CUMC builds on a collaboration Rosetta announced earlier this month in which the Henry Ford Hospital is providing Rosetta with samples of metastases found in brain tissue (see RNAi News, 5/3/2007).
Rosetta has said that its CUP diagnostic could reach the US market by next year.
Qiagen to Distribute Whatman's DNA-Storage Technology
Qiagen said this week that it will distribute Whatman's FTA DNA-handling products under a non-exclusive agreement.
Under the agreement, Qiagen will pay an upfront fee and royalties for the rights to sell the kits in the life science research, molecular diagnostics, and applied-testing markets.
The royalty payments will apply to all Qiagen sales that incorporate Whatman's products.
Whatman's FTA instruments and FTA-based kits use "a chemically treated matrix" that lyses cells, immobilizes nucleic acids, and allows researchers to collect, transport, archive, and release DNA at room temperature.
Qiagen said the FTA line is "highly synergistic" with its sample-prep technology portfolio, and that it expects the combination of tools to be useful in forensics, pharmacogenomics, biobanking, and genomics research.
Thermo Adds TSQ Quantum Tools to BRIMS Program as Goals Move Downstream
Thermo Fisher Scientific said last week it has expanded its Biomarker Research Initiative in Mass Spectrometry program to include new technology and programs that involve clinical validation and clinical application assays.
The BRIMS program, begun in 2004 with Massachusetts General Hospital, initially focused on discovering protein biomarkers, particularly those related to cardiovascular disease. It was intended to use Thermo’s LTQ FT and LTQ Orbitrap and other tools with Mass General’s bank of plasma samples.
BRIMS will now use Thermo’s TSQ Quantum triple-quadrupole platform and its TurboFlow sample-prep technology to develop assays for peptides and protein-biomarker quantitation.
Correction: In its May 10 issue, RNAi News incorrectly reported that Traversa Therapeutics was in the process of filing US and international patent applications on its delivery technology (see RNAi News, 5/10/2007).
In fact, the company has already filed the applications, but is awaiting their publication and issuance.